Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-26T09:08:05.593Z Has data issue: false hasContentIssue false
  • English
  • Français

A Market Shaping Approach for the Biopharmaceutical Industry: Governing Innovation Towards the Public Interest

Published online by Cambridge University Press:  21 April 2021

Mariana Mazzucato  and
Henry Lishi Li
Get access Rights & Permissions [Opens in a new window]

Abstract

Enhancing research and development and ensuring equitable pricing and access to cutting-edge treatments are both vital to a biopharmaceutical innovation system that works in the public interest. However, despite delivering numerous therapeutic advances, the existing system suffers from major problems: a lack of directionality to meet key needs, inefficient collaboration, high prices that fail to reflect the public contribution, and an overly-financialized business model.

Keywords

PharmaceuticalInnovationPricingAccessGovernance
Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 49 , Issue 1: Public Sector and Non-Profit Contributions to Drug Development: Historical Scope, Opportunities, and Challenges , Spring 2021 , pp. 39 - 49
Copyright
© 2021 The Author(s)

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barrenho, E., Miraldo, M., and Smith, P.C., “Does Global Drug Innovation Correspond to Burden of Disease? The Neglected Diseases in Developed and Developing Countries,” Health Economics 28, no. 1 (2017): 123–143, doi:10.1002/hec.3833CrossRefGoogle Scholar
Rattingen, J.A. et al., “Mapping of Available Health Research and Development Data: What’s There, What’s Missing, and What Role is there for a Global Observatory?” Lancet 382, no. 9900 (2013): 1286–1307.CrossRefGoogle Scholar
Pedrique, B. et al., “The Drug and Vaccine Landscape for Neglected Diseases (2000-11): A Systematic Assessment,” Lancet Global Health 1, no. 6 (2013): e371–9.CrossRefGoogle Scholar
Dowden, H. and Munro, J., “Trends in Clinical Success Rates and Therapeutic Focus,” Nature Reviews. Drug Discovery 18, no. 7 (2019): 495–496.CrossRefGoogle Scholar
Feldman, R., “May Your Drug Price Be Ever Green,” SSRN (2017), doi:10.2139/ssrn.3061567; J.K. Aronson and A.R. Green, “Me-Too Pharmaceutical Products: History, Definitions, Examples, and Relevance to Drug Shortages and Essential Medicines Lists,” British Journal of Clinical Pharmacology 86, no. 11 (2020): 2114-2122, doi:10.1111/bcp.14327.Google Scholar
Feldman, supra note 5.Google Scholar
“New Drugs and Indications in 2014: Some Advances this Year, but Many Drugs are Poorly Evaluated too Expensive, or More Dangerous than Useful,” Prescrire International 24, no. 159 (2015): 107–110.Google Scholar
Plüss, J.D., “With No Prospects for Profits, Big Pharma Neglects New Infectious Diseases,” SWI swissinfo.ch (2020), available at >https://www.swissinfo.ch/eng/covid-19_with-no-prospects-for-profits--big-pharma-turns-back-on-new-infectious-diseases/45598436> (last visited January 8, 2021).https://www.swissinfo.ch/eng/covid-19_with-no-prospects-for-profits--big-pharma-turns-back-on-new-infectious-diseases/45598436>+(last+visited+January+8,+2021).>Google Scholar
Menachery, V.D. et al., “A SARS-Like Cluster of Circulating Bat Coronaviruses Shows Potential for Human Emergence,” Nature Medicine 21 (2015): 1508–1513; W.H. Chen, U. Strych, P.J. Hotez, and M.E. Bottazzi, “The SARS-CoV-2 Vaccine Pipeline: an Overview,” Current Tropical Medicine Reports 7, no. 2 (2020): 61-64; OECD, Treatments and a Vaccine for COVID-19: The Need for Coordinating Policies on R&D, Manufacturing and Access - OECD (2020).CrossRefGoogle Scholar
Mazzucato, M. and Roy, V., “Rethinking Value in Health Innovation: From Mystifications Towards Prescriptions,” Journal of Economic Policy Reform 22, no. 2 (2019): 101–119; G.P. Pisano, Science Business: The Promise, the Reality, and the Future of Biotech (Harvard Business School Press, 2006).CrossRefGoogle Scholar
Miller, J.E., Wilenzick, M., Ritcey, N., Ross, J.S., and Mello, M.M., “Measuring Clinical Trial Transparency: An Empirical Analysis of Newly Approved Drugs and Large Pharmaceutical Companies,” BMJ Open 7, no. 12 17917 (2017); J.E. Miller, D. Korn, and J.S. Ross, “Clinical Trial Registration, Reporting, Publication and FDAAA compliance: A Cross-Sectional Analysis and Ranking of New Drugs Approved by the FDA in 2012,” BMJ Open 5, no. 11 (2015): e009758; R. Chen et al., “Publication and Reporting of Clinical Trial Results: Cross Sectional Analysis Across Academic Medical Centers,” BMJ 35 (2016).CrossRefGoogle Scholar
Salman, R. Al-Shahi et al., “Increasing Value and Reducing Waste in Biomedical Research Regulation and Management,” The Lancet 383, no. 9912 (2014): 176–185; M. Dijkers, “Reduce, Reuse, Recycle: Good Stewardship of Research Data,” Spinal Cord 57 (2019): 165-166; B. Owens, “Data Sharing: Access All Areas,” Nature 533 (2016): S71-S72.CrossRefGoogle Scholar
Mazzoleni, R. and Nelson, R.R., “Economic Theories about the Benefits and Costs of Patents,” Journal of Economic Issues 32, no. 4 (1998): 1031–1052; F. Orsi, C. Sevilla, and B. Coriat, “Upstream Patents and Public Health: The Case of Genetic Testing for Breast Cancer,” in Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech, eds. M. Mazzucato and G. Dosi (Cambridge University Press, 2006): 327-345, doi:10.1017/CBO9780511493232.011.CrossRefGoogle Scholar
Heller, M.A. and Eisenberg, R.S., “The Tragedy of the Commons,” Science 162, no. 3859 (1968): 1243–1248.Google Scholar
Røttingen, supra note 2.Google Scholar
Mazzucato, supra note 10.Google Scholar
Rizvi, Z., “Blind Spot: How the COVID-19 Outbreak Shows the Limits of Pharma’s Monopoly Model,” (2020), available at <https://www.citizen.org/article/blind-spot/> (last visited February 22, 2021).+(last+visited+February+22,+2021).>Google Scholar
“The Real Story of Remdesivir,” Public Citizen, May 7, 2020, available at <https://www.citizen.org/article/the-real-story-of-remdesivir/?eType=EmailBlastContent&eId=9bdafb07-71bb-41dc-8726-f80183f3f648> (last visited January 11, 2021).+(last+visited+January+11,+2021).>Google Scholar
Institute for Clinical and Economic Review, “ICER Comments on Gilead’s Pricing for Remdesivir,” 2020, available at <https://icer-review.org/blog/icer-comments-on-gileads-pricing-for-remdesivir/> (last visited January 11, 2021).+(last+visited+January+11,+2021).>Google Scholar
Mazzucato, supra note 10.Google Scholar
Lazonick, W., Hopkins, M., Jacobson, K., Sakinc, M., and Tulum, O., “US Pharma’s Financialized Business Model,” Institute for New Economic Thinking Working Paper Series No. 60 (2017), doi:10.2139/ssrn.3035529; R. Collington, “Profits, Innovation and Financialization in the Insulin Industry,” Institute for New Economic Thinking Working Paper Series (2020): 1-36, doi:10.36687/inetwp120.Google Scholar
Tulum, Ö. and Lazonick, W., “Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry,” International Journal of Political Economy 47, no. 3-4 (2018): 281–316.Google Scholar
Arora, A. and Gambardella, A., “The Division of Innovative Labor in Biotechnology,” in Sources of Medical Technology: Universities and Industry (1995): 188–206.Google Scholar
Roy, V. and King, L., “Betting on Hepatitis C: How Financial Speculation in Drug Development Influences Access to Medicines,” BMJ 354, no. i3718 (2016); K. Birch, “Rethinking Value in the Bio-economy: Finance, Assetization, and the Management of Value,” Science Technology and Human Values 42, no. 3 (2017): 460–490.Google Scholar
Whitfill, T., “Biopharma Companies are Taking Advantage of their Misinformation,” STAT (2020), available at <https://www.statnews.com/2020/05/26/biopharma-companies-spreading-misinformation-taking-advantage-of-it/> (last visited January 11, 2021).Google Scholar
Andreoni, A. and Chang, H.J., “Industrial Policy and the Future of Manufacturing,” Economia e Politica Industriale 43, no. 4 (2016): 491–502.CrossRefGoogle Scholar
Badreldin, H. A. and Atallah, B., “Global Drug Shortages Due to COVID-19: Impact on Patient Care and Mitigation Strategies,” Research in Social and Administrative Pharmacy 17, no. 1 (2020), doi:10.1016/j.sapharm.2020.05.017; L.L. Ouel-lette, N. Price, R. Sachs, and J. Sherkow, “How Can the US Address Coronavirus Drug Shortages?” Written Description (2020), available at <https://writtendescription.blogspot.com/2020/04/how-can-us-address-coronavirus-drug.html> (last visited January 11, 2021).Google Scholar
Mazzucato, M., “The Covid-19 Crisis is a Chance to do Capitalism Differently,” The Guardian (2020), available at <https://www.theguardian.com/commentisfree/2020/mar/18/the-covid-19-crisis-is-a-chance-to-do-capitalism-differently> (last visited January 11, 2021).+(last+visited+January+11,+2021).>Google Scholar
Arrow, K.J., “Economic Welfare and the Allocation of Resources for Invention,” in Readings in Industrial Economics (Macmillan Education UK, 1972): 219–236, doi:10.1007/978-1-349-15486-9_13; M. Mazzucato, “From Market Fixing to Market-Creating: A New Framework for Innovation Policy,” Industry and Innovation 23, no. 2 (2016): 140-156.CrossRefGoogle Scholar
Stiglitz, J.E. and Weiss, A., “Credit Rationing in Markets with Rationing Credit Information Imperfect,” American Economic Review 71, no. 3 (1981): 393–410; R. H. Coase, “The Problem of Social Cost,” Journal of Law and Economics 3 (1960).Google Scholar
Stern, N., The Economics of Climate Change: The Stern Review (Cambridge University Press, 2007).CrossRefGoogle ScholarPubMed
Mazzucato, M., The Entrepreneurial State: Debunking Public vs. Private Sector Myths (Penguin Books, 2013), doi:10.1016/S1386-6532(09)70080-0; M. Mazzucato, The Value of Everything: Making and Taking in the Global Economy (Allen Lane, 2017), doi:10.1084/jem.20030973.Google Scholar
Mazzucato, supra note 29.Google Scholar
Fleming, L., Greene, H., Li, G., Marx, M., and Yao, D., “Government-Funded Research Increasingly Fuels Innovation,” Science 364, no. 6446 (2019): 1139–1141.CrossRefGoogle Scholar
Mazzucato, The Entrepreneurial State, supra note 32; V.W. Ruttan, Is War Necessary for Economic Growth?: Military Procurement and Technology Development. Is War Necessary for Economic Growth?: Military Procurement and Technology Development (Oxford University Press, 2006), doi:10.1093/01 95188047.001.0001; F. Block and M. Keller, “State of Innovation: The U.S. Government’s Role in Technology Development,” Choice Reviews Online 48, no. 6 (2011): 48-3394-48-3394.Google Scholar
Mazzucato, The Entrepreneurial State, supra note 32.Google Scholar
Mazzucato, The Entrepreneurial State, supra note 32.Google Scholar
Nayak, R.K., Avorn, J., and Kesselheim, A.S., “Public Sector Financial Support for Late Stage Discovery of New Drugs in the United States: Cohort Study,” BMJ 367, no. l5766 (2019); W. Lazonick and M. Mazzucato, “The Risk-Reward Nexus in the Innovation-Inequality Relationship: Who Takes the Risks? Who Gets the Rewards?” Industrial and Cororate Change 22, no. 4 (2013): 1093–1128.Google Scholar
Sampat, B.N. and Lichtenberg, F.R., “What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?” Health Affairs 30, no. 2 (2011): 332–339; A.J. Stevens et al., “The Role of Public-Sector Research in the Discovery of Drugs and Vaccines,” New England Journal of Medicine 364, no. 6 (2011): 535-541.CrossRefGoogle ScholarPubMed
Sussex, J., “Quantifying the Economic Impact of Government and Charity Funding of Medical Research on Private Research and Development Funding in the United Kingdom,” BMC Medicine 14, no. 1 (2016), article 32; M. Deleidi, M. Mazzucato, and G. Semieniuk, “Neither Crowding in Nor Out: Public Direct Investment Mobilising Private Investment into Renewable Electricity Projects,” Energy Policy 140, no. 111195 (2020).CrossRefGoogle Scholar
Azoulay, P., Zivin, J.S. Graff, Li, D., and Sampat, B.N., “Public R&D Investments and Private-Sector Patenting: Evidence from NIH Funding Rules,” Review of Economic Study 86, no. 1 (2018): 117–152.CrossRefGoogle Scholar
Laplane, A. and Mazzucato, M., “Socializing the Risks and Rewards of Public Investments: Economic, Policy, and Legal Issues,” Research Policy: X 2 (2020), article 100008.Google Scholar
Nelson, R.R. and Winter, S.G., An Evolutionary Theory of Economic Change (Belknap Press of Harvard University Press, 1982).Google Scholar
The Real Story of Remdesivir, supra note 18.Google Scholar
Hoffman, S.J. and Outterson, K., “What Will it Take to Address the Global Threat of Antibiotic Resistance?” Journal of Law, Medicine & Ethics 43, no. 2 (2015): 363–368; A. S. Kesselheim, J. Avorn, and A. Sarpatwari, “The High Cost of Prescription Drugs in the United States Origins and Prospects for Reform,” JAMA 316, no. 8 (2016): 858-871.CrossRefGoogle ScholarPubMed
Mazzucato, M., Mission-Oriented Research and Innovation in the European Union: A Problem-Solving Approach to Fuel Innovation-Led Growth. (European Commission, 2018), doi:10.2777/36546.Google Scholar
Id., Department for Business Energy & Industrial Strategy, Industrial Strategy: Building a Britain Fit for the Future, Department for Business Energy and Industrial Strategy (2017), doi:10.1049/ir:19930092.CrossRefGoogle Scholar
Mowery, D.C., Nelson, R.R., and Martin, B.R., “Technology Policy and Global Warming: Why New Policy Models are Needed (Or Why Putting New Wine in Old Bottles Won’t Work) Research Policy 39, no. 8 (2010): 1011–1023; J. Edler and L. Georghiou, “Public Procurement and Innovation-Resurrecting the Demand Side,” Research Policy 36, no. 7 (2007): 949-963.CrossRefGoogle Scholar
Mowery, D.C., “Military R&D and Innovation,” Handbook of the Economics of Innovation 2, no. 1 (2010): 1219–1256; W.B. Bonvillian, “DARPA and its ARPA-E and IARPA Clones: A Unique Innovation Organization Model,” Industrial and Corporate Change 27, no. 5 (2018): 897-914.CrossRefGoogle Scholar
UCL Institute for Innovation and Public Purpose, The People’s Prescription: Re-Imagining Health Innovation to Deliver Public Value, IIPP Policy Report (IIPP, Global Justice Now, Just Treatment and STOPAIDS, 2018).Google Scholar
Edler, supra note 48.Google Scholar
Pardi, N., Hogan, M.J., Porter, F.W., and Weissman, D., “mRNA Vaccines — A New Era in Vaccinology,” Nature Reviews. Drug Discovery 17, no. 4 (2018): 261–279; J. Hodgson, “The Pandemic Pipeline,” Nature Biotechnology 38, no. 5 (2020): 523-532.CrossRefGoogle Scholar
Office of the Senate Democrats, The Endless Frontier Act, introduced by Senate Democratic Leader Chuck Schumer (D-NY), Senator Todd Young (R-IN), Congressman Ro Khanna (D-CA), and Congressman Mike Gallagher (R-WI) (2020).Google Scholar
UCL Commission for Mission-Oriented Innovation and Industrial Strategy, A Mission-Oriented UK Industrial Strategy 106 (2019).Google Scholar
Burlamaqui, L., Castro, A.C., and Kattel, R., Knowledge Governance: Reasserting the Public Interest (Anthem Press, 2011), doi:10.7135/UPO9780857285522.Google Scholar
Mazzoleni, supra note 13; Orsi, supra note 13.Google Scholar
Pigott, R., Barker, R., and Kaan, T., and Roberts, M., Shaping the Future of Open Innovation: A Practical Guide for Life Sciences Organisations (Wellcome Trust, 2014).Google Scholar
Lezaun, J. and Montgomery, C.M.M., “The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development,” Science Technology & Human Values 40, no. 1 (2015): 3–29.CrossRefGoogle Scholar
Balasegaram, M. et al., “An Open Source Pharma Roadmap,” PLoS Medicine 14, no. 4 (2017).CrossRefGoogle Scholar
Lezaun, supra note 58.Google Scholar
Bountra, C., Lee, W.H., and Lezaun, J., A New Pharmaceutical Commons: Transforming Drug Discovery, Oxford Martin Policy Paper (2017).Google Scholar
Årdal, C. and Røttingen, J.A., “Open Source Drug Discovery in Practice: A Case Study,” PLoS Neglected Tropical Diseases 6, no. 9 (2012).CrossRefGoogle Scholar
Balasegaram, supra note 59.Google Scholar
Wong, H., “The Case for Compulsory Licensing During COVID-19,” Journal of Global Health 10, no. 1 (2020).CrossRefGoogle Scholar
Id., Bassi, L.L. and Hwenda, L., “COVID-19: Time to Plan for Prompt Universal Access to Diagnostics and Treatments,” The Lancet Global Health 8, no. 6 (2020): E756-E757.CrossRefGoogle ScholarPubMed
Nature Editorials, “Coronavirus: everyone wins when patents are pooled,” Nature 581, no. 7808 (2020); World Health Organization, COVID-19 technology access pool (2020), available at <https://www.who.int/emergencies/diseases/novel-corona-virus-2019/global-research-on-novel-coronavirus-2019-ncov/covid-19-technology-access-pool> (last visited January 13, 2021).+(last+visited+January+13,+2021).>Google Scholar
Schacht, W.H., Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship (2011).Google Scholar
Sarpatwari, A., LaPidus, A.K., and Kesselheim, A.S., “Revisiting the National Institutes of Health Fair Pricing Condition: Promoting the Affordability of Drugs Developed with Government Support,” Annals of Internal Medicine 172, no. 5 (2020): 348–350.CrossRefGoogle Scholar
Mazzucato, The Entrepreneurial State, supra note 32.Google Scholar
Burlamaqui, supra note 55.Google Scholar
Brumfiel, G., “Labs Bottoms Out,” Nature 454, no. 7207 (2008): 927; G. Eliasson, “Advanced Purchasing, Spillovers and Innovative Discovery,” Journal of Evolutionary Economics 21, no. 1 (2011): 121-139, E.M. Da Fonseca, K. Shadlen, and F. I. Bastos, “Integrating Science, Technology and Health Policies in Brazil: Incremental Change and Public Health Professionals as Agents of Reform,” Journal of Latin American Studies 51 (2019): 357-377.CrossRefGoogle Scholar
Mazzucato, M. and Torreele, E., “How to Develop a COVID-19 Vaccine for All,” Project Syndicate (2020), available at <https://www.project-syndicate.org/commentary/universal-free-covid19-vaccine-by-mariana-mazzucato-and-els-tor-reele-2020-04> (last visited January 13, 2021).+(last+visited+January+13,+2021).>Google Scholar
Khan, I., Ramaphosa, C., et al., “Uniting Behind A People’s Vaccine Against COVID-19,” (2020), available at <https://oi-files-d8-prod.s3.eu-west-2.amazonaws.com/s3fs-public/2020-05/ENGLISH--Uniting-Behind-a-Peoples-Vaccine-AgainstCO-VID-19-1305201720.pdf> (February 22, 2021).+(February+22,+2021).>Google Scholar
Lazonick, W. and Tulum, Ö., “US Biopharmaceutical Finance and the Sustainability of the Biotech Business Model,” Research Policy 40, no. 9 (2011): 1170–1187.CrossRefGoogle Scholar
Lazonick, W., “Profits Without Prosperity: How Stock Buy-backs Manipulate the Market and Leave Most Americans Worse Off,” Institute for New Economic Thinking Conference Paper (2014), available at <https://www.ineteconomics.org/research/research-papers/profits-without-prosperity-how-stock-buybacks-manipulate-the-market-and-leave-most-americans-worse-off> (last visited February 22, 2021).+(last+visited+February+22,+2021).>Google Scholar
Warren, E., Text — S.3348 — 115th Congress (2017-2018): Accountable Capitalism Act. (2018).Google Scholar
Chang, H. and Andreoni, A., “Industrial Policy in the 21st Century,” Development and Change 51, no. 2 (2020): 324–351, doi:10.1111/dech.12570.CrossRefGoogle Scholar
Office of U.S. Senator Elizabeth Warren of Massachusetts, COVID-19 Emergency Manufacturing Act of 2020, introduced by Senator Elizabeth Warren (D-MA) and Representative Jan Schakowsky (D-IL) (2020).Google Scholar
Chang, supra note 77; Pisano, G.P., and Shih, W.C., Producing Prosperity: Why America Needs a Manufacturing Renaissance (Harvard Business Press, 2012); A. Andreoni, “The Architecture and Dynamics of Industrial Ecosystems: Diversification and Innovative Industrial Renewal in Emilia Romagna,” Cambridge Journal of Economics 42, no. 6 (2018):1613-1642.CrossRefGoogle Scholar
Whitfill, supra note 25.Google Scholar
Bowden, J., “Rubio, Warren to introduce pharmaceutical supply chain review legislation,” The Hill, June 30, 2020, available at <https://thehill.com/homenews/senate/505188-rubio-warren-to-introduce-pharmaceutical-supply-chain-review-measure-report> (last visited January 13, 2021).+(last+visited+January+13,+2021).>Google Scholar
Mazzucato, M., Li, H.L., and Darzi, A., “Is it Time to Nationalise the Pharmaceutical Industry?” BMJ 368 (2020); G. Sitaraman and A.L. Alstott, The Public Option: How to Expand Freedom, Increase Opportunity, and Promote Equality (Harvard University Press, 2019); D. Brown, Medicine for All: The Case for a Public Option in the Pharmaceutical Industry (2019), available at <https://thenextsystem.org/medicineforall> (last visited February 22, 2021).Google ScholarPubMed
Singer, A.C., Kirchhelle, C., and Roberts, A.P., “(Inter)nationalis-ing the Antibiotic Research and Development Pipeline,” Lancet Infectious Disease 20, no. 2 (2019): E54–E62, doi:10.1016/S1473-3099(19)30552-3.CrossRefGoogle Scholar